BTIG analyst Mark Massaro maintained a Hold rating on Cerus (CERS – Research Report) on December 28. The company’s shares closed last Friday at $2.16.
According to TipRanks, Massaro is an analyst with an average return of -15.6% and a 33.00% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Ginkgo Bioworks Holdings, and MDxHealth S.A. Sponsored ADR.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cerus with a $4.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
CERS market cap is currently $391.4M and has a P/E ratio of -7.77.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus (CERS) Company Description:
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Read More on CERS:
